

PATENT  
Attorney Docket No. P-154-US1  
Customer No. 27038

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
LINSELL et al.	)	
	)	Confirmation No.: 3562
Application No.: 10/627,555	)	
	)	Group Art Unit: 1621
Filed: July 25, 2003	)	
	)	Examiner: Shailendra Kumar
For: CRYSTALLINE $\beta_2$ ADRENERGIC	)	
RECEPTOR AGONIST	)	
	)	

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants respectfully submit this Information Disclosure Statement (IDS) in conformance with 37 C.F.R. §§1.97 and 1.98 for the above-identified patent application.

The filing of this IDS shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information submitted herewith is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)) of the subject application.

Pursuant to 37 C.F.R. §1.98(a)(2)(ii), copies of U.S. patents and U.S. patent application publications cited on the accompanying PTO Form PTO/SB/08a are not being submitted.

Applicants respectfully request that the Examiner consider all of the documents cited on the accompanying PTO Form PTO/SB/08a. After such consideration, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicants with the next Office Action on the merits.

This IDS is being filed after the mailing date of the first Office Action on the merits, but before the mailing date of a final action under 37 C.F.R. §1.113. Accordingly, this IDS is accompanied by the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). The Commissioner is hereby authorized to charge any fees for submission of this paper to Deposit Account No. 50-0344.

Any questions regarding this IDS should be directed to the undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: April 18, 2008

By: /Roberta P. Saxon/  
Roberta P. Saxon, Ph. D.  
Registration No. 43,087

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078